In summary, our phase II trial of E7820 in patients with R/R, splicing factor-mutant myeloid malignancies provides proof-of-concept that splicing factor-mutant disease can be targeted in humans via RBM39 degradation. Here, SLU7 is linked to myeloid neoplasm.